SEC Form 4 · accession 0001209191-19-002674
Verrica Pharmaceuticals Inc. · VRCA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul B Manning
Director · 10% Owner
Period of report
Jan 7, 2019
Accepted (ET)
Jan 7, 2019 · 8:51 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001660334
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 7, 2019 | P | 12,775 | $10.41 | A | 8,035,658 | D | |
| Common StockF3,F4 | Jan 7, 2019 | P | 20,116 | $11.55 | A | 8,055,774 | D | |
| Common StockF5,F6 | Jan 7, 2019 | P | 2,734 | $11.99 | A | 8,058,508 | D | |
| Common StockF1,F7 | Jan 7, 2019 | P | 4,258 | $10.41 | A | 1,299,602 | I | See Footnote |
| Common StockF3,F7 | Jan 7, 2019 | P | 6,706 | $11.55 | A | 1,306,308 | I | See Footnote |
| Common StockF5,F7 | Jan 7, 2019 | P | 911 | $11.99 | A | 1,307,219 | I | See Footnote |
| Common StockF8 | holding | — | — | — | 256,634 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $9.87 to $10.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F2Consists of 7,754,783 shares of common stock held by Mr. Manning and 280,875 shares of common stock held by Mr. Manning jointly with his spouse.
- F3The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $10.98 to $11.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F4Consists of 7,754,783 shares of common stock held by Mr. Manning and 300,991 shares of common stock held by Mr. Manning jointly with his spouse.
- F5The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $11.98 to $12.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F6Consists of 7,754,783 shares of common stock held by Mr. Manning and 303,725 shares of common stock held by Mr. Manning jointly with his spouse.
- F7The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of BKB and has sole voting and investment power with respect to the shares held by BKB.
- F8The shares are held directly by PBM Capital Investments, LLC ("PBMCI"). The Reporting Person is President and CEO of PBMCI and has sole voting and investment power with respect to the shares held by PBMCI.